Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Indivior Pharmaceuticals, Inc. - Common Stock (NQ:INDV)

36.13 +0.42 (+1.18%)
Delayed Quote Updated: 9:33 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Indivior Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
Payment of Special Dividend Contingent upon Closing of the Pending Merger Transaction 
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether INDV, FHB, BGMS are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Shows Breakout Setup With Perfect Technical Strength Score ↗
Via Chartmill
Indivior Pharmaceuticals (NASDAQ:INDV) Passes Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Smashes Q1 Estimates and Lifts Full-Year Outlook as SUBLOCADE Sales Surge ↗
Via Chartmill
News headline image
Indivior Q2 2026 Earnings Call: Complete Transcript ↗
Indivior (NASDAQ:INDV) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For... 
Via Benzinga
Topics Earnings
News headline image
Why Supernus Pharmaceuticals Stock Topped the Market Today ↗
It's effecting a "merger of equals" with a peer. 
Via The Motley Fool
News headline image
Halper Sadeh LLC is Investigating Whether LNTH, ATKR, INDV are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Shows High Growth Momentum and Technical Breakout Potential ↗
Via Chartmill
News headline image
Indivior Q2 Earnings Call Highlights ↗
Supernus Pharmaceuticals and Indivior (NASDAQ:INDV) announced plans to combine in an all-stock, tax-free merger of equals that the companies said would create a central nervous system-focused... 
Via MarketBeat
Topics Earnings
News headline image
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
From Supernus Pharmaceuticals, Inc.; Indivior Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry? ↗
Indivior, a leader in opioid dependence therapies, reported a notable insider sale following a year of exceptional share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This Fund's $74.8 Million Indivior Sale ↗
Indivior develops buprenorphine-based treatments for opioid dependence, serving markets in the US, UK, and worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200% ↗
Indivior develops buprenorphine-based therapies for opioid dependence, serving healthcare providers and treatment centers worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This Fund's $61.5 Million Exit From Ecovyst Amid a 75% Stock Rally ↗
Ecovyst delivers catalysts and sulfuric acid services to global refining and chemical industries with advanced process solutions. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior to Participate in Upcoming Investor Conferences
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Why One Fund Made a $23 Million Bet on This Addiction-Treatment Stock Amid a Staggering Rally ↗
Indivior develops proprietary treatments for opioid dependence, generating revenue from specialty pharmaceuticals across global markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Indivior Announces $175 Million Accelerated Share Repurchase
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior (INDV) Q1 2026 Earnings Transcript ↗
Indivior (INDV) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.